Molecular Imaging and Radionuclide Therapy最新文献

{"title":"Atypical Presentation of Metastatic Castrate-resistant Prostate Cancer in a Middle Aged African Male with Good Response to Radioligand Therapy.","authors":"Osayande Evbuomwan, Walter Endres, Tebatso Tebeila, Gerrit Engelbrecht","doi":"10.4274/mirt.galenos.2023.13471","DOIUrl":"10.4274/mirt.galenos.2023.13471","url":null,"abstract":"<p><p>Prostate cancer typically follows a characteristic pattern of metastatic spread to the pelvic lymph nodes and bone. Atypical patterns of metastasis are rare but have been documented. In African men, this disease tends to follow a more aggressive course, with the possibility of an atypical site of metastatic spread. We present a case of a 58-year- old African male with metastatic castrate-resistant prostate cancer who presented with both typical and atypical patterns of metastatic disease detected by a fluorine 18 prostate-specific membrane antigen positron emission tomography/computed tomography scan. This patient also had a good response to radioligand therapy.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"57-62"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Rare Benign Lesions on ¹⁸F-FDG PET/CT: Peliosis Hepatis and SANT.","authors":"Ediz Beyhan, Ahu Senem Demiröz, İbrahim Taşkın Rakıcı, Tevfik Fikret Çermik, Esra Arslan","doi":"10.4274/mirt.galenos.2023.02328","DOIUrl":"10.4274/mirt.galenos.2023.02328","url":null,"abstract":"<p><p>Peliosis hepatis (PH) and sclerosing angiomatoid nodular transformation of the spleen are uncommon benign lesions. Diagnosis can be difficult in some patients. Herein, we present the case of a 28-year-old woman referred with abdominal pain who had spleen lesions. ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography revealed multiple non-FDG avid lesions in the liver and hypermetabolic lesions in the spleen. In addition, abdominal magnetic resonance imaging was performed. Histopathology revealed sclerosing angiomatoid nodular transformation in the spleen and PH in the liver.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"43-46"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT Imaging for Treatment Response Assessment of Cardiac Primitive Neuroectodermal Tumor.","authors":"Mehmet Emin Mavi, Murat Fani Bozkurt","doi":"10.4274/mirt.galenos.2023.91259","DOIUrl":"10.4274/mirt.galenos.2023.91259","url":null,"abstract":"<p><p>Primitive neuroectodermal tumors (PNETs) are rare and aggressive members of the small round cell carcinoma family. Generally, PNETs are classified into two main groups: PNETs of the central nervous system and PNETs of the peripheral nervous system. Herein, we report the therapy response assessment of a rare case of isolated cardiac PNET using ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) imaging. Given that physiological cardiac FDG uptake is typically observed, assessing FDG avid lesions in the myocardium presents a challenge for FDG PET/CT. This case holds significance because of the rarity of the disease and the challenging nature of the site for FDG PET/CT imaging.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"50-53"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptionally Rare Isolated Thyroidal Metastasis of Pulmonary Carcinosarcoma: A Tale of ¹⁸F-FDG-positive Thyroid Nodule.","authors":"Mehmet Emin Mavi, Fariba Amini, Seyfettin Ilgan","doi":"10.4274/mirt.galenos.2023.74507","DOIUrl":"10.4274/mirt.galenos.2023.74507","url":null,"abstract":"<p><p>Pulmonary carcinosarcomas (PCS) are uncommon and aggressive malignant tumors with epithelial and mesenchymal components and have a worse prognosis than other non-small-cell lung cancers. Metastases of non-thyroidal malignancies to the thyroid are rare. We reported a unique case of isolated thyroidal metastasis of PCS and discussed ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positivity in incidentally found thyroid nodules on ¹⁸F-FDG positron emission tomography scan.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"63-65"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga Prostate-specific Membrane Antigen Uptake in Metastatic Medullary Thyroid Carcinoma.","authors":"Kübra Şahin, Ali Kibar, Cansu Güneren, Muhammet Sait Sağer, Kerim Sönmezoğlu","doi":"10.4274/mirt.galenos.2023.47855","DOIUrl":"10.4274/mirt.galenos.2023.47855","url":null,"abstract":"<p><p>We present the case of a 58-year-old man with advanced medullary thyroid carcinoma who had a treatment history with different types of modalities. In the follow-up, the patient had rising calcitonin and CEA levels. Metastatic lymph nodes, liver, and bone metastases with varying degrees of uptake were detected on ¹⁸F-fluorodeoxyglucose (FDG) and ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography (PET/CT). ⁶⁸Ga prostate-specific membrane antigen (PSMA) PET/CT was performed to explore whether the patient might have a chance for PSMA-targeted radionuclide therapy, and increased PSMA expression was noted in most of the metastatic lesions, even some of which have higher PSMA uptake than ¹⁸F-FDG and ⁶⁸Ga-DOTATATE.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"54-56"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"About the Article Titled \"A Different Scintigraphic Perspective on the Systolic Function of the Left Ventricle-1\".","authors":"Cengiz Taşçı","doi":"10.4274/mirt.galenos.2023.69345","DOIUrl":"10.4274/mirt.galenos.2023.69345","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"66-67"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer.","authors":"Carlos Avila, Tatiana Cadavid, Maria Cristina Martínez, Humberto Varela, Nathalie Hernández-Hidalgo","doi":"10.4274/mirt.galenos.2023.82653","DOIUrl":"10.4274/mirt.galenos.2023.82653","url":null,"abstract":"<p><strong>Objectives: </strong>To present a clinical care model for the administration of 177Lu-labeled prostate-specific membrane antigen (PSMA) in radiometabolic therapy for metastatic castration-resistant prostate cancer (mCRPC) at the National Cancer Institute (NCI) of Bogotá, Colombia.</p><p><strong>Methods: </strong>A care model was designed for patients with mCRPC based on the VISION study, a prospective, phase III, multicenter, open-label, randomized study in patients with positive ⁶⁸Ga-PSMA positron emission tomography/computed tomography who had progressed to taxane and androgen therapy, to receive 177Lu-PSMA-617 combined with the best standard of care vs. the best standard of care alone. The care pathway provided to patients was developed by the Nuclear Medicine Group of the NCI and is the result of adjustments and improvements in the care process and the updating of the literature.</p><p><strong>Results: </strong>A systematic and efficient care model was formalized and implemented for the administration of 177Lu-PSMA therapy in patients with mCRPC who had previously been treated with at least one androgen receptor pathway inhibitor and one or two taxane regimens, with evidence of disease progression.</p><p><strong>Conclusion: </strong>An optimized process of care based on the determinants of clinical outcomes was developed for patients who received this type of radiometabolic therapy.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"28-37"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Added-value of Staging ¹⁸F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.","authors":"Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak","doi":"10.4274/mirt.galenos.2023.65002","DOIUrl":"10.4274/mirt.galenos.2023.65002","url":null,"abstract":"<p><strong>Objectives: </strong>This retrospective study aimed to evaluate the prognostic importance of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging ¹⁸F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.</p><p><strong>Methods: </strong>Bladder cancer patients who underwent staging ¹⁸F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUV_max) of primary tumors, total numbers, sizes, and SUV_max of ¹⁸F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUV_max of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.</p><p><strong>Results: </strong>Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had ¹⁸F-FDG positive pelvic LNs, while 24 (43.7%) patients had ¹⁸F-FDG positive extra-pelvic disease. Patients with ¹⁸F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of ¹⁸F-FDG-positive pelvic LNs (p<0.001) and ¹⁸F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The ¹⁸F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.</p><p><strong>Conclusion: </strong>The presence of ¹⁸F-FDG-positive extra-pelvic disease in pretreatment ¹⁸F-FDG PET/CT is an important prognostic factor in bladder cancer patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"11-18"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone and Parathyroid Scintigraphy Findings in Sagliker Syndrome.","authors":"Çağlagül Erol, Özlem Şahin, Ahmet Eren Şen, Zeynep Aydın","doi":"10.4274/mirt.galenos.2023.24382","DOIUrl":"10.4274/mirt.galenos.2023.24382","url":null,"abstract":"<p><p>Sagliker syndrome (SS) is a rare, exaggerated form of chronic kidney disease (CKD)-mineral and bone disorder resulting from untreated secondary hyperparathyroidism due to CKD. Herein, we describe a 34-year-old male patient whose Tc-99m-methylene diphosphonate bone scintigraphy and Tc-99m-sestamibi parathyroid scintigraphy revealed hints of SS and exhibited its defining characteristics.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"40-42"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular Incidentaloma on 18F-choline PET/CT in a Patient with Prostatic Adenocarcinoma","authors":"Chaymae Bensaid, Salah Oueriagli Nabih, Meryem Aboussabr, O. Sahel, Y. Benameur, A. Doudouh","doi":"10.4274/mirt.galenos.2024.76259","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.76259","url":null,"abstract":"Prostatic adenocarcinoma is characterized by elevated phosphatidylcholine metabolism. 18 F-choline positron emission tomography/computed tomography (PET/CT) is widely used for patients with biochemical recurrence and a prostate-specific antigen threshold above 2 ng/mL. We report a case of a patient with high-risk prostatic adenocarcinoma undergoing 18 F-choline PET/CT for biochemical recurrence. In addition to hypermetabolic abdominal lymph nodes, an unexpected right testicular hypermetabolism was observed. Such findings on 18 F-choline PET/CT may suggest a primary tumor or testicular metastasis of prostate cancer. Bilateral orchiectomy revealed a vitelline tumor associated with known primary prostatic cancer. The incidental discovery of a testicular vitelline tumor during prostate cancer imaging is rare, highlighting the importance of thorough diagnostics. This case underscores the need for comprehensive care in managing complex and atypical cancer cases, emphasizing the potential for unrelated tumor discoveries during diagnostic workup. Further research is essential for a better understanding of these rare co-occurring cancers and their treatment implications","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"285 ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140448136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}